Overview

Cosopt Versus Xalatan

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pharmaceutical Research Network
Treatments:
Dorzolamide
Latanoprost
Maleic acid
Timolol
Criteria
Inclusion Criteria:

- adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular
hypertenstion

- intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H

- ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

- any contraindications to study medications

- any anticipated change in systemic hypertensive therapy during the trial